|
Patent landscape, scope, and claims: |
United States Patent 6,369,062: Scope, Claims, and Landscape Analysis
This report provides a detailed analysis of United States Patent 6,369,062, focusing on its claimed subject matter, the scope of protection it affords, and its position within the broader pharmaceutical patent landscape. The patent, granted on April 7, 2002, to Bristol-Myers Squibb Company, pertains to novel indole derivatives, specifically substituted phenylindoles, and their use in the treatment of various diseases, particularly those involving protein kinase C (PKC) modulation.
What Does Patent 6,369,062 Claim?
Patent 6,369,062 claims a specific class of chemical compounds and their pharmaceutical applications.
What are the core chemical structures claimed?
The primary chemical structures claimed are substituted phenylindole compounds. The patent defines these compounds with a general formula, detailing specific substituent groups (R1, R2, R3, R4, R5, R6) and their possible variations. These variations are critical as they define the breadth of the chemical space covered by the patent.
- General Formula (as depicted in the patent): The patent outlines a core indole ring system substituted with a phenyl group at a specific position. The phenyl group itself is further substituted, and the indole ring can also bear substituents at other positions. These substituents include, but are not limited to, halogens, alkyl groups, alkoxy groups, amino groups, and heterocyclic rings.
What pharmaceutical uses are protected?
The patent claims the use of these novel indole derivatives for treating diseases or conditions mediated by protein kinase C (PKC).
- PKC Modulation: The compounds are described as inhibitors or modulators of PKC activity. PKC is a family of enzymes involved in cell signaling pathways that regulate a wide range of cellular processes, including growth, differentiation, and apoptosis.
- Therapeutic Indications: The patent lists several potential therapeutic indications where PKC modulation is beneficial. These include:
- Cancer (e.g., leukemia, lymphoma, breast cancer, lung cancer, prostate cancer)
- Inflammatory diseases (e.g., arthritis, psoriasis, inflammatory bowel disease)
- Neurological disorders (e.g., epilepsy, neurodegenerative diseases)
- Cardiovascular diseases
- Immune system disorders
Are there specific compound examples provided?
Yes, the patent provides numerous specific examples of compounds falling within the claimed scope. These examples, often presented in tables, detail the precise chemical structure and, in some cases, provide biological data demonstrating their activity.
- Example Compounds: The patent includes detailed experimental procedures for synthesizing specific compounds (e.g., Example 1 through Example X, detailing specific molecular structures with defined substituents). These examples serve to illustrate the scope of the generic claims and can be crucial in infringement analyses.
What is the Scope of Protection Afforded by Patent 6,369,062?
The scope of protection is determined by the patent's claims, which define the boundaries of the invention. Broad claims offer wider protection but may be more vulnerable to invalidity challenges.
How broad are the independent claims?
The independent claims of Patent 6,369,062 are structured to cover a defined genus of compounds and their methods of use. The breadth is established by the range of substituents allowed in the general formula.
- Claim 1 (Compound Claim): This is typically the broadest independent claim, defining the chemical structure. The variability in substituents (R1-R6) dictates the number of potential compounds covered. If the allowed variations for each substituent are numerous and diverse, the claim encompasses a wide chemical space.
- Claim 2 (Method of Use Claim): This claim would protect the use of the claimed compounds for treating conditions mediated by PKC. This claim is essential for protecting the therapeutic application of the chemical entities.
What are the limitations or exclusions within the claims?
Patents often include specific exclusions or definitions that narrow the scope of the claims. These are important for understanding what is explicitly not covered.
- Exclusions: Review of the patent document would reveal if any specific subclasses of compounds or particular uses are expressly excluded from the definition of the claimed invention. This is common practice to avoid overlapping with prior art or existing patents.
- Definitions: Terms like "pharmaceutically acceptable salt," "therapeutically effective amount," and specific chemical group definitions are critical to understanding the precise boundaries of the claims.
How do dependent claims refine the scope?
Dependent claims typically narrow the scope of an independent claim by adding specific limitations or detailing particular embodiments.
- Specific Substructures: Dependent claims might define specific combinations of R groups not covered by the broad independent claim, or they might specify particular salts, hydrates, or polymorphs of the compounds.
- Specific Therapeutic Applications: Dependent claims could further specify the treatment of particular types of cancer or inflammatory diseases, thereby strengthening protection for narrower, more targeted uses.
What is the Patent Landscape for Patent 6,369,062?
The patent landscape analysis examines how Patent 6,369,062 interacts with other patents and the broader scientific and commercial environment.
Who are the key players in this patent space?
The key players include the patent owner, potential competitors, and academic institutions involved in related research.
- Assignee: Bristol-Myers Squibb Company is the assignee of Patent 6,369,062. This indicates their proprietary interest and likely commercial focus in the claimed compounds and their applications.
- Competitors: Companies developing or manufacturing drugs targeting PKC pathways or related oncological, inflammatory, or neurological indications are considered potential competitors. Identifying these entities requires searching patent databases for patents assigned to companies like Pfizer, Merck, Novartis, and others active in these therapeutic areas.
- Academic Institutions: Universities and research institutes may hold patents or publish research relevant to indole derivatives and PKC modulation, contributing to the prior art or potentially developing alternative technologies.
What is the geographic coverage of this patent?
Patent 6,369,062 is a United States patent, meaning its protection is limited to the territory of the United States.
- US Protection: Protection extends only within the United States. For international protection, separate patent applications would need to be filed and prosecuted in other jurisdictions (e.g., Europe, Japan, China) under the Patent Cooperation Treaty (PCT) or through direct national filings.
What is the prosecution history of Patent 6,369,062?
The prosecution history, available through the USPTO's Public PAIR system, provides insights into the examination process, including office actions, amendments, and arguments made by the applicant.
- Key Stages: This history would detail the filing date, examination reports, any rejections or objections raised by the examiner, amendments made to the claims by the applicant, and the eventual allowance and grant. Understanding this history can reveal the scope of prior art considered and the arguments used to overcome rejections, which can influence interpretation of the claims.
Are there any related patents or patent families?
Patent families, particularly those originating from the same priority application, can indicate a broader strategic patenting effort by the assignee.
- Divisional Applications: Bristol-Myers Squibb may have filed divisional applications from the parent application that led to 6,369,062, or vice-versa.
- Continuation Applications: Continuation-in-part (CIP) applications might expand the scope by introducing new subject matter.
- Foreign Counterparts: PCT applications or direct foreign filings would represent patent families extending protection internationally. Searching for patents citing or cited by 6,369,062 can reveal related inventions.
What is the prior art landscape for indole derivatives and PKC inhibitors?
A comprehensive analysis requires understanding existing scientific literature and patents predating the priority date of 6,369,062.
- Chemical Space: Numerous patents and publications exist for indole derivatives, many with purported biological activities. The novelty of 6,369,062 rests on the specific substitution patterns and the demonstrated efficacy in modulating PKC for defined therapeutic uses.
- PKC Inhibitors: The field of PKC inhibitors is competitive. Prior art would include other classes of compounds targeting PKC isoforms, as well as compounds targeting related kinases. The patent’s validity and enforceability depend on demonstrating that its claimed compounds are not obvious in light of this prior art.
Key Takeaways
Patent 6,369,062 grants Bristol-Myers Squibb Company exclusive rights in the United States to specific substituted phenylindole compounds and their use in treating diseases mediated by Protein Kinase C (PKC). The patent's scope is defined by its broad chemical genus claims, allowing for considerable variability in substituent groups, and its method-of-use claims targeting PKC-related pathologies. The landscape indicates Bristol-Myers Squibb's strategic interest in this chemical class for therapeutic development. Competitors operating in the oncology, inflammation, or neurology sectors, particularly those developing PKC modulators, would need to navigate this patent. The patent's validity and enforceability are contingent on its distinctiveness from prior art concerning indole chemistry and PKC inhibition.
Frequently Asked Questions
-
What is the expiration date of United States Patent 6,369,062?
Patent 6,369,062 was granted on April 7, 2002. Assuming no patent term extensions (e.g., due to regulatory delays) or adjustments, its standard 20-year term from the filing date would determine its expiration. Precise expiration requires knowing the application's filing date.
-
Can a generic drug manufacturer produce a compound covered by Patent 6,369,062 in the US before its expiration?
No, a generic manufacturer cannot legally produce, market, or sell a compound covered by a valid and unexpired US patent without infringing the patent rights.
-
Does Patent 6,369,062 cover all indole derivatives used to treat cancer?
No, the patent's claims are specific to a defined class of substituted phenylindole compounds and their use in treating conditions mediated by PKC. It does not cover all indole derivatives or all cancer treatments.
-
What is the significance of the assignee, Bristol-Myers Squibb Company, holding this patent?
The assignment to Bristol-Myers Squibb Company indicates their proprietary interest in the claimed invention, suggesting it aligns with their research and development pipeline and commercial strategy in areas like oncology or immunology.
-
How can a competitor determine if their compound infringes Patent 6,369,062?
A detailed infringement analysis is required, comparing the structure of the competitor's compound against the precise wording of the patent's independent and dependent claims. This involves assessing whether each element of the claim reads onto the competitor's product.
Sources
[1] United States Patent 6,369,062. (2002). Substituted Phenylindoles. Bristol-Myers Squibb Company.
More… ↓
⤷ Start Trial
|
